Immusoft is a startup based in the United States, 2 tracked investors.
Based in the United States, Immusoft is a startup. Brouky records 2 investors associated with the company.
Immusoft engineers patient-derived B cells to become therapeutic protein-producing plasma cells, which are infused back into patients to provide durable and personalized protein therapies.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.